Loading...

APC anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6dot7_APC_041106
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
  • 53-6dot7_APC_041106
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
100711 25 µg 27€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100712 100 µg 84€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Choi JG, et al. 2020. Front Immunol. 11:598556. PubMed
  2. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  3. Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed
  4. Behr FM, et al. 2021. Eur J Immunol. 51:151. PubMed
  5. Thomas R, et al. 2021. Immunology. 163:478. PubMed
  6. Zhou Y, et al. 2021. Methods Mol Biol. 2388:35. PubMed
  7. Schenkel JM, et al. 2021. Immunity. 54:2338. PubMed
  8. Kragten NAM, et al. 2022. Eur J Immunol. 52:389. PubMed
  9. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  10. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  11. Yue Y, et al. 2022. Nat Biomed Eng. 6:898. PubMed
  12. Aghayev T, et al. 2022. Cancer Discov. 12:1960. PubMed
  13. Zhao Z, et al. 2022. Adv Sci (Weinh). 9:e2201293. PubMed
  14. Blanco LP, et al. 2022. Arthritis Rheumatol. 74:1971. PubMed
  15. Marié IJ, et al. 2022. Bio Protoc. 12:e4438. PubMed
  16. Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed
  17. Xie DH, et al. 2022. Med Phys. 49:6728. PubMed
  18. Chen Y, et al. 2023. Adv Healthc Mater. 12:e2202085. PubMed
  19. Theofilatos D, et al. 2022. STAR Protoc. 3:101839. PubMed
  20. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  21. You Q, et al. 2023. Adv Mater. 35:e2204910. PubMed
  22. Yu J, et al. 2022. Nat Commun. 13:7903. PubMed
  23. Morrow RJ, et al. 2022. Cells. 11: . PubMed
  24. Zhao X, et al. 2022. STAR Protoc. 3:101859. PubMed
  25. Ding D, et al. 2023. J Med Chem. 66:1467. PubMed
  26. Lin J, et al. 2023. Nat Commun. 14:224. PubMed
  27. Smith LA, et al. 2023. Front Oncol. 12:1031174. PubMed
  28. Ali LR, et al. 2023. J Exp Med. 220: . PubMed
  29. Kasuya T, et al. 2023. Sci Rep. 13:1653. PubMed
  30. Wang R, et al. 2023. NPJ Vaccines. 8:6. PubMed
  31. Meng S, et al. 2023. Stem Cell Investig. 10:2. PubMed
  32. Zheng J, et al. 2023. Biomater Res. 27:9. PubMed
  33. Zhao M, et al. 2023. J Nanobiotechnology. 21:50. PubMed
  34. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  35. Ye L, et al. 2022. Cell Metab. 34:595. PubMed
  36. Mise Y, et al. 2022. Carcinogenesis. 43:647. PubMed
  37. Stone VM, et al. 2022. iScience. 25:105070. PubMed
  38. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  39. Puth S, et al. 2022. Biomaterials. 286:121542. PubMed
  40. Guo A, et al. 2022. Nature. 607:135. PubMed
  41. Chen R, et al. 2022. J Mol Cell Biol. 14:. PubMed
  42. Konjar S, et al. 2022. Proc Natl Acad Sci U S A. 119:e2202144119. PubMed
  43. Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed
  44. Pagni RL, et al. 2022. Front Immunol. 13:1005937. PubMed
  45. Chen H, et al. 2023. Nat Commun. 14:941. PubMed
  46. Li X, et al. 2023. J Clin Invest. 133:. PubMed
  47. Kozlovski S, et al. 2023. Front Immunol. 13:1041552. PubMed
  48. Saha S, et al. 2023. Sci Rep. 13:4609. PubMed
  49. Do-Thi VA, et al. 2023. Cancer Res Commun. 3:80. PubMed
  50. Shi Y, et al. 2023. Nat Commun. 14:1884. PubMed
  51. Huang T, et al. 2023. Front Immunol. 14:1124152. PubMed
  52. Wu N, et al. 2023. Front Bioeng Biotechnol. 11:1173381. PubMed
  53. Zhang YT, et al. 2023. Front Immunol. 14:1085456. PubMed
  54. Zhang J, et al. 2023. Theranostics. 13:2226. PubMed
  55. Yu L, et al. 2023. Front Oncol. 13:1174713. PubMed
  56. He Y, et al. 2023. Biomolecules. 13:. PubMed
  57. Deng G, et al. 2023. Cancers (Basel). 15:. PubMed
  58. Wang Y, et al. 2023. iScience. 26:106630. PubMed
  59. Wang K, et al. 2023. Nat Commun. 14:2950. PubMed
  60. Wang D, et al. 2023. Nat Commun. 14:2943. PubMed
  61. Li M, et al. 2023. BMC Cancer. 23:497. PubMed
  62. Zeng S, et al. 2023. Front Oncol. 13:1171926. PubMed
  63. Lan Y, et al. 2023. iScience. 26:106817. PubMed
  64. Zhang AQ, et al. 2023. Nat Biomed Eng. . PubMed
  65. Song S, et al. 2023. Bioact Mater. 28:358. PubMed
  66. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  67. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  68. Schuster M, et al. 2017. J Immunol. 199:920. PubMed
  69. Li X et al. 2019. Immunity. 50(3):576-590 . PubMed
  70. O'Malley G, et al. 2018. Cancer Immunol Res. 1.240277778. PubMed
  71. Jiang W, et al. 2017. Sci Rep. 7:6501. PubMed
  72. Xu X, et al. 2020. Chin Med. 15:33. PubMed
  73. Renrick AN, et al. 2021. Front Immunol. 607044:12. PubMed
  74. Bian L, et al. 2022. Front Immunol. 13:938598. PubMed
  75. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
  76. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  77. Zhao X, et al. 2022. Front Mol Biosci. 9:786864. PubMed
  78. Jiang Q, et al. 2022. Theranostics. 12:59. PubMed
  79. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  80. Paris J et al. 2019. Cell Stem Cell. 25(1):137-148 . PubMed
  81. Espinosa-Cueto P, et al. 2017. PLoS One.. 10.1371/journal.pone.0182126. PubMed
  82. Ma Z, et al. 2016. Clin Cancer Res. 22: 2969 - 2980. PubMed
  83. Iwasaki Y, et al. 2016. PLoS One. 11: 0158282. PubMed
  84. Leach SM, et al. 2020. Cell Rep. 33:108337. PubMed
  85. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  86. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  87. Dong L, et al. 2021. Cancer Cell. . PubMed
  88. Castiello MC, et al. 2020. J Allergy Clin Immunol. . PubMed
  89. Rodriguez-García A, et al. 2021. Nat Commun. 12:877. PubMed
  90. Pan Y, et al. 2021. Front Cell Neurosci. 15:664312. PubMed
  91. Hewitson JP, et al. 2020. J Immunol. 204:2949. PubMed
  92. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  93. Jiang W, et al. 2021. Oncol Lett. 22:625. PubMed
  94. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  95. Li ZX, et al. 2022. Arch Virol. :. PubMed
  96. Ghosh S, et al. 2022. APL Bioeng. 6:036105. PubMed
  97. Bauer KM, et al. 2022. JCI Insight. 7:. PubMed
  98. Wang D, et al. 2018. Immunity. 48:659. PubMed
  99. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  100. Song C, et al. 2019. Nat Commun. 10:3745. PubMed
  101. Takeda Y, et al. 2018. Innate Immun. 24:323. PubMed
  102. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  103. Riley JS, et al. 2020. Blood Adv. 4:1102. PubMed
  104. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  105. Hirano KI, et al. 2021. eLife. 0.416666666666667. PubMed
  106. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  107. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  108. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  109. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
  110. del Rio ML, et al. 2021. Transl Res. Online ahead of print.. PubMed
  111. Tian H, et al. 2022. Cancer Sci. 113:875. PubMed
  112. Zhao J, et al. 2022. J Nanobiotechnology. 20:62. PubMed
  113. Blumenthal D, et al. 2020. eLife. 9:e55995.. PubMed
  114. Chakrabarti J, et al. 2018. Oncotarget. 9:37439. PubMed
  115. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  116. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  117. Felker A, Croy B 2016. J Leukoc Biol. 100: 645 - 655. PubMed
  118. Wagner V, et al. 2016. Sci Transl Med. 8: 366ra164. PubMed
  119. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  120. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  121. Bommireddy R, et al. 2020. Vaccines (Basel). 8:. PubMed
  122. Yin Y, et al. 2021. ACS Nano. 15:14347. PubMed
  123. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  124. Chen S et al. 2018. Cell reports. 25(7):1729-1740 . PubMed
  125. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  126. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  127. Zhang F, et al. 2019. Nat Commun. 10:3974. PubMed
  128. Lee JH, et al. 2018. Transgenic Res. 27:241. PubMed
  129. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  130. Zhan CS, et al. 2020. FASEB J. 14006:34. PubMed
  131. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  132. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  133. Lebratti T, et al. 2021. eLife. 10:00. PubMed
  134. Eriksson E, et al. 2016. Gene Ther. 10.1038/gt.2016.80. PubMed
  135. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  136. Guo H, et al. 2022. PLoS Pathog. 18:e1010857. PubMed
  137. Frey N, et al. 2022. Nat Commun. 13:1804. PubMed
  138. Zhang J, et al. 2022. Front Immunol. 13:931740. PubMed
  139. Bhattacharya P, et al. 2022. PLoS Negl Trop Dis. 16:e0010224. PubMed
  140. Zhan Y, et al. 2021. JCI Insight. 6:. PubMed
  141. Zhang C, et al. 2020. Cell Metabolism. 31(1):148-161.e5.. PubMed
  142. Lu Y, et al. 2020. Cell. 180(6):1081-1097. PubMed
  143. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  144. Li Y, et al. 2019. Oncol Rep. 41:2679. PubMed
  145. Tran L, et al. 2017. Cancer Immunol Res. 5:1141. PubMed
  146. Yin Q, et al. 2015. PLoS One. 10: 0137808. PubMed
  147. Vieyra-Garcia P, et al. 2016. Clin Cancer Res. 22: 3328 - 3339. PubMed
  148. Matsumura K, et al. 2016. J Immunol. 197: 3233 - 3244. PubMed
  149. Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed
  150. Wang L, et al. 2021. Cancer Immunol Res. 9:348. PubMed
  151. Si L, et al. 2022. Nat Biotechnol. 40:1370. PubMed
  152. Ebina-Shibuya R, et al. 2021. Elife. 10:. PubMed
  153. Solanki A, et al. 2018. Development. 145. PubMed
  154. Koliaraki V et al. 2019. Cell reports. 26(3):536-545 . PubMed
  155. Zhang F, et al. 2019. Immunity. 50:738. PubMed
  156. Riffelmacher T et al. 2017. Immunity. 47(3):466-480 . PubMed
  157. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  158. Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
  159. Aegerter H, et al. 2020. Nat Immunol. 0.975694444. PubMed
  160. Poczobutt J, et al. 2016. J Immunol. 196: 891 - 901. PubMed
  161. He X, et al. 2021. Small. 17:e2007165. PubMed
  162. Pervaiz N, et al. 2021. Pigment Cell Melanoma Res. 34:918. PubMed
  163. Katsinas N, et al. 2022. J Clin Med. 11:. PubMed
  164. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  165. Jeong SH, et al. 2021. Nat Commun. 12:4405. PubMed
  166. Brummer G, et al. 2020. Oncogene. 39:2275. PubMed
  167. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  168. Soldevilla MM, et al. 2019. Mol Ther. 27:1878. PubMed
  169. Liu D et al. 2019. Immunity. 51(1):64-76 . PubMed
  170. Luo Y et al. 2019. Cell reports. 26(7):1869-1879 . PubMed
  171. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  172. Liu J, et al. 2019. J Exp Med. 216:656. PubMed
  173. Funk KE, et al. 2019. J Neuroinflammation. 16:22. PubMed
  174. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  175. Divan A, et al. 2018. PLoS One. 13:e0196893. PubMed
  176. Chen Q, et al. 2016. Nat Commun. 7:13193. PubMed
  177. Hoefflin R, et al. 2020. Nat Commun. 3.313194444. PubMed
  178. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  179. Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed
  180. Lee JS et al. 2018. Cell. 174(6):1559-1570 . PubMed
  181. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  182. Zheng Z, et al. 2020. Cell Death Dis. 0.684722222. PubMed
  183. Xu H, et al. 2020. Immunity. 51(4):696-708.e9.. PubMed
  184. Tartey S, et al. 2021. Cancer Research. 81(9):2358-2372. PubMed
  185. Elahi S, et al. 2020. Stem Cell Res. 43:101710. PubMed
  186. Bayik D, et al. 2020. Cancer Discov. 1.256944444. PubMed
  187. Yi X, et al. 2020. Sci Adv. 6:eaba3546. PubMed
  188. Vidy A, et al. 2016. PLoS One. 11:e0165361. PubMed
  189. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  190. He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed
  191. Liu T, et al. 2022. Front Immunol. 13:901349. PubMed
  192. Zhang C, et al. 2022. Nat Commun. 13:3468. PubMed
  193. Goldfarb Y, et al. 2021. J Exp Med. 218:. PubMed
  194. Ye P, et al. 2022. Front Cardiovasc Med. 8:810477. PubMed
  195. Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
  196. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  197. Horiguchi H, et al. 2019. Genes Dev. 33:1641. PubMed
  198. Bai C, et al. 2020. Mol Ther Oncolytics. 17:9. PubMed
  199. Leal AS, et al. 2019. Sci Rep. 5.286111111. PubMed
  200. Al–Zaher AA, et al. 2018. Mol Ther Oncolytics. 0.376388889. PubMed
  201. Li W, et al. 2019. Nat Commun. 10:3349. PubMed
  202. Budida R, et al. 2017. Eur J Immunol. 47:1819. PubMed
  203. Reismann D, et al. 2017. Nat Commun.. 10.1038/s41467-017-01538-9. PubMed
  204. Ishidome T et al. 2017. EBioMedicine. 22:89-99 . PubMed
  205. Gibbins J, et al. 2014. Blood. 124:2953. PubMed
  206. Ku C, et al. 2015. Genes Dev. 29: 1930-1941. PubMed
  207. Cook KD, et al. 2015. Immunity. 43:703-714. PubMed
  208. Latasa C, et al. 2016. PLoS One. 11: 0161216. PubMed
  209. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  210. Wanner-Seleznik GM, et al. 2020. Immunohorizons. 0.644444444. PubMed
  211. Zeng W, et al. 2021. STAR Protocols. 2(1):100361. PubMed
  212. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  213. Oka Y, et al. 2020. Sci Adv. 6:. PubMed
  214. Haas MS, et al. 2020. Mol Cancer Res. 19:717. PubMed
  215. Jiang Y, et al. 2020. Adv Mater. 32:e2001808. PubMed
  216. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  217. Li H, et al. 2021. Nat Commun. 12:7149. PubMed
  218. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  219. Wu H, et al. 2021. Cell Death Discov. 7:225. PubMed
  220. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  221. Zhang Q, et al. 2022. Nat Commun. 13:2406. PubMed
  222. Germundson DL, et al. 2022. Front Allergy. 3:870513. PubMed
  223. Li YN, et al. 2022. Nat Commun. 13:4074. PubMed
  224. Ren W, et al. 2018. Mucosal Immunol. 12:531. PubMed
  225. Hu J, et al. 2019. Mol Ther Nucleic Acids. 16:650. PubMed
  226. Matsuo K, et al. 2018. J Immunol. 200:800. PubMed
  227. Takaku S, et al. 2020. Integr Cancer Ther. 19:1534735419900798. PubMed
  228. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  229. Medyouf H, et al. 2010. Blood. 115:1175. PubMed
  230. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  231. Oguri Y, et al. 2020. Cell. 182(3):563-577.e20. PubMed
  232. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  233. Yang Z, et al. 2021. Onco Targets Ther. 14:4239. PubMed
  234. Otvos B, et al. 2021. Clin Cancer Res. 27:2038. PubMed
  235. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  236. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  237. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  238. Lin W, et al. 2019. EBioMedicine. 49:133. PubMed
  239. Chen Z, et al. 2019. J Exp Med. 216:152. PubMed
  240. Nam GH, et al. 2018. Nat Commun. 9:2165. PubMed
  241. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  242. Sun S, et al. 2013. J Immunol. 190:6209. PubMed
  243. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  244. Nanou A, et al. 2021. Cell Reports. 35(8):109168. PubMed
  245. Hu Y, et al. 2021. Cell Death Dis. 12:743. PubMed
  246. Schreiber K, et al. 2020. Cancer Immunol Res. 8:192. PubMed
  247. Feng Y, et al. 2022. J Nanobiotechnology. 20:193. PubMed
  248. Lin YH, et al. 2018. Cancer Immunol Res. 0.25. PubMed
  249. Morelli AE, et al. 2020. Cell Rep. 30:3448. PubMed
  250. Zhang NN, et al. 2020. Cell. 182(5):1271-1283. PubMed
  251. Mohamed E, et al. 2020. Immunity. 52(4):668-682.e7.. PubMed
  252. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  253. Alexandre YO, et al. 2020. Cell Reports. 33(13):108567. PubMed
  254. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
  255. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  256. Wu L, et al. 2020. Cell Rep. 33:108327. PubMed
  257. Swanson P, et al. 2016. PLoS Pathog. 12:e1006022. PubMed
  258. Teo T, et al. 2015. J Virol. 89: 7955-7969. PubMed
  259. Sasaki Y, et al. 2015. PLoS One. 10: 0131176. PubMed
  260. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  261. Takahashi F, et al. 2022. iScience. 25:104278. PubMed
  262. Qi J, et al. 2021. Nat Commun. 12:4755. PubMed
  263. Robertson TF, et al. 2021. J Cell Biol. 220:. PubMed
  264. Nasarre P, et al. 2021. Cancers (Basel). 13: . PubMed
  265. Li X, et al. 2021. Cell Death Dis. 12:314. PubMed
  266. Spangenberg E, et al. 2019. Nat Commun. 10:3758. PubMed
  267. Frazer GL, et al. 2021. J Cell Biol. 220:. PubMed
  268. Do-Thi VA, et al. 2021. Cancers (Basel). 13:. PubMed
  269. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  270. Kataru RP, et al. 2022. Front Aging. 3:864860. PubMed
  271. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  272. Huber MK, et al. 2021. J Vis Exp. :. PubMed
  273. Chen H, et al. 2022. Front Pharmacol. 13:827520. PubMed
  274. Dallari S, et al. 2021. Cell Host Microbe. 29(6):1014-1029.e8. PubMed
  275. Ma Q, et al. 2022. Vaccines (Basel). 10:. PubMed
  276. Fonderflick L, et al. 2022. Cells. 11:. PubMed
  277. Rao L, et al. 2020. Nat Commun. 11:4909. PubMed
  278. Murata T, et al. 2020. Sci Rep. 10:13560. PubMed
  279. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  280. Zheng Z, et al. 2021. Nat Commun. 12:6202. PubMed
  281. Kiss M, et al. 2020. Cancer Immunol Res. 9:309. PubMed
  282. Ulaganathan VK, et al. 2020. Sci Rep. 10:8453. PubMed
  283. Li X, et al. 2017. Front Immunol. 8:1186. PubMed
  284. Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed
  285. Tassi I, et al. 2014. J Immunol. 193:4303. PubMed
  286. Kramer K, et al. 2017. Mol Ther. 25(1):62-70. PubMed
  287. Zheng DW, et al. 2020. Nat Commun. 3.865972222. PubMed
  288. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  289. Lu C, et al. 2020. Cancer Cell. 39(1):96-108.e6. PubMed
  290. Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed
  291. Zheng Z, et al. 2021. Biomed Res Int. 2021:5535578. PubMed
  292. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  293. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  294. Harrison DK, et al. 2021. Transplantation. 105:540. PubMed
  295. Gaya M et al. 2018. Cell. 172(3):517-533 . PubMed
  296. Zhang J, et al. 2018. Oncoimmunology. 7:e1461301. PubMed
  297. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  298. Chao Y, et al. 2020. Sci Adv. 6:eaaz4204. PubMed
  299. Kataru RP, et al. 2019. Cancer Immunol Res. 7:1345. PubMed
  300. Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed
  301. Pelly V, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.4. PubMed
  302. Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed
  303. Liu YW, et al. 2022. JCI Insight. 7:. PubMed
  304. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  305. Chen B, et al. 2021. Cell. 184:6262. PubMed
  306. Smith LK, et al. 2021. Elife. 10:. PubMed
  307. Nagatake T, et al. 2021. Int Immunol. 33:171. PubMed
  308. Tang-Huau TL, et al. 2021. Viruses. 13: . PubMed
  309. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  310. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  311. Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed
  312. Tippimanchai DD, et al. 2018. Oncoimmunology. 7:e1438105. PubMed
  313. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
  314. Cong L, et al. 2021. Breast Cancer Res. 23:51. PubMed
  315. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  316. Zhou P, et al. 2022. Mol Ther Oncolytics. 25:236. PubMed
  317. Zheng Y, et al. 2022. Transl Res. :. PubMed
  318. Funk KE, et al. 2021. Aging Cell. 20:e13412. PubMed
  319. Konishi Y, et al. 2018. iScience. 10:98. PubMed
  320. Wang J, et al. 2020. J Hematol Oncol. 0.610416667. PubMed
  321. Galeano Nio JL, et al. 2020. eLife. 9:00. PubMed
  322. Zhang Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  323. Bessell CA, et al. 2020. JCI Insight. 5:. PubMed
  324. Li C, et al. 2022. Front Cell Dev Biol. 10:913824. PubMed
  325. Tseng SH, et al. 2021. J Biomed Sci. 28:63. PubMed
  326. Li X, et al. 2021. Front Immunol. 12:779560. PubMed
  327. Liu WL, et al. 2019. Nat Commun. 10:3199. PubMed
  328. Johnson JL et al. 2018. Immunity. 48(2):243-257 . PubMed
RRID
AB_312750 (BioLegend Cat. No. 100711)
AB_312750 (BioLegend Cat. No. 100712)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD8alpha
Specificity Alt (DOES NOT SHOW ON TDS):
CD8a
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD8alpha on UniProt.org

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV395™ anti-mouse CD8a 53-6.7 FC
PerCP/Fire™ 780 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01/21/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account